http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) are recommended to use as the first-line nucleoside analogues (NAs) in patients with chronic hepatitis B (CHB) due to their potent viral suppression with a lower risk of drug resistance and excellent preventive effect for hepatocellular carcinoma (HCC) development. However, the effects of ETV and TDF on HCC development in CHB patients have not been fully examined. Methods: The aims of the current study were therefore to compare the effects of ETV and TDF therapy on HCC development in CHB patients in clinical practice. A total of 1,412 ETV-naïve patients and 1,318 TDF-naı¨ve patients were enrolled into the study. Results: The baseline characteristics of both groups were no significant difference. Virological and biochemical responses were similar between the two therapy groups over time. During a median 26 months of follow-up (range 1.0-60 months), 126 patients (4.6%) developed HCC. The 1-, 2-, 3- and 5-year cumulative HCC incidence rates in all cases were 2.2%, 3.8%, 5.1% and 9.9%, respectively. There was no significant difference in cumulative rates of HCC carcinoma (HCC) development (log-rank P = 0.357) between the two therapy groups. Multivariate analysis showed that male, older age, cirrhosis, lower albumin levels and HBeAg-positve status were independently associated with HCC development. Conclusions: HCC incidence and virological response were similar between ETV and TDF therapy groups in CHB patients in clinical practice. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with CHB due to their potent viral suppression and similar effect for HCC development.
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Rare data are available on the comparison of tenofovir (TDF) and entecavir (ETV) therapy in chronic hepatitis B patients with baseline high viral load (HVL) in clinical practice, defined as having hepatitis B virus (HBV) DNA >8 log10 copies/mL (7.3 log10 IU/mL). Methods: We performed a retrospective analysis of the efficacy of TDF therapy, as compared to that of ETV therapy, in patients with HVL. A matched study population was constructed to compare the antiviral efficacy of TDF therapy and ETV therapy by a propensity score analysis. Results: Three hundreds two patients were selected after matching propensity score with 1:1 ratio. Virologic response (VR) was observed in 63.6% (96/151) of patients in the TDF group and in 64.2% (97/151) of the patients in the ETV group. The VR rates were not different between the TDF and ETV groups (51.5 vs. 51.4% at month 12, and 72.1 vs. 69.2% at month 24; log rank P = 0.432). During therapy, 70.2% of patients in the TDF group, and 74.8% of patients in the ETV group had partial VR, respectively (P=0.367). ALT normalization rates also did not differ between both the treatment groups (94.3% and 92.1% in the TDF and ETV therapy groups, respectively; P = 0.838). Nineteen patients experienced a virological breakthrough. Among them, 7 patients (4.6 %) was in the TDF group and 12 patients (7.9 %) were in the ETV group (P = 0.236). During therapy, 21.2% (28 of 132) of patients in the TDF group, and 19.1% (25 of 131) of patients in the ETV group achieved HBeAg seroconversion, respectively (P = 0.667). In multivariate analysis, absolute HBV DNA level at baseline (P<0.001), HBeAg-positive status (P< 0.001) and ALT levels at baseline (P =0.044) were significantly associated with VR. Conclusions: In patients with HVL >8 log10 copies/mL (7.3 log10 IU/mL), virological and biochemical responses were similar between ETV and TDF therapy groups in CHB patients. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with HVL..
( Yun Im Lee ),( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park,),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Very limited data are available on long-tern efficacy of Tenofovir (TDF) rescue regimens in patients with multi-drug resistance (MDR). In this study, we evaluated the efficacy of TDF-based rescue therapy in chronic hepatitis B (CHB) patients after the failure of multiple nucleos( t)ide (NA) therapies. Methods: The study retrospectively analyzed 133 CHB patients who experienced failure with two or more NAs and who were switched to regimens containing TDF. Results: Prior to TDF-based rescue therapy, resistance to both LAM (rt180, rt204) and ADV (rt181, rt236) was present in 51 patients, and 73 patients had resistance to both LAM and ETV (rt173, rt184, rt202, rt250). The other 9 patients had resistance to LAM, ADV, and ETV. The mean HBV DNA level at baseline was 4.35 ± 1.75 log10 IU/mL. The study subjects were treated with TDF montherapy (n=23), TDF/lamivudine (LAM) (n=47), or TDF/entecavir (ETV) combination therapy (n=63) for more than 6 months. Virologic response (VR) occurred in 119 (89.5%) patients. PVR was evident in 50 (37.6%) patients. At a median duration of 48 months of TDF treatment, the cumulative probabilities of achieving VR were 56.4%, 66.3%, 82.8%, 86.7%, and 91.2% at 6, 12, 24, 36, and 48 months, respectively. The VR rates were not affected by types of MDR (log rank P = 0. 260). Among the pretreatment factors, lower baseline HBV DNA level (P < 0.001) and TDF/ETV or TDF/LAM combination therapy group (P =0.049) were significantly associated with VR in the univariate analysis. In multivariate analysis, absolute HBV DNA level at the start of TDF rescue treatment (P<0.001; OR, 0.652; 95% CI, 0.574-0.741) was only significantly associated with VR. There were no significant clinical adverse events during rescue treatment. Conclusions: TDF was an efficient and safe rescue therapy for CHB patients after treatment failure with multiple NAs. On the current data, TDF-based combination therapy seemed to be no better than those achieved by monotherapy. To verify the efficacy and safety of TDF based rescue regimen, further large cohort studies with a long follow-up duration are warranted
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Tenofovir (TDF) therapy has been recommended as a rescue strategy for chronic hepatitis B (CHB) patients with nucleos(t)ide (NA) resistance. Unfortunately, after sequential NA monotherapy in CHB patients with lamivudine (LAM) resistance, multidrug resistance (MDR) developed in a substantial number of patients. Very limited data are available on the comparison of TDF therapy between single drug resistant (SDR) and MDR groups in NA-resistant CHB patients. Methods: Of the 269 CHB patients with NA-resistance, 139 were SDR group and 130 were MDR group. A matched study population was constructed to compare the antiviral efficacy of TDF therapy by a propensity score analysis. Results: Two hundreds CHB patients were selected after matching propensity score with 1:1 ratio. The median follow-up period during TDF therapy was 47.3 months (range, 6-59 months). Virologic response (VR) occurred in 188 patients (95 patients in the SDR group and 93 patients in the MDR group) during the treatment period. The VR rate was lower in the MDR group than in the SDR group but statistically insignificant (74.3% vs. 85.6% at month 12, and 87.4% vs. 92.2% at month 24; log rank P=0.111). Partial virologic response (PVR) rates were not different between both groups (20.0% and 31.0% in the SDR and MDR groups, respectively; P = 0.105). The rates of ALT normalization and HBeAg seroconvesion also did not differ between both groups (P>0.05). In multivariate analysis, absolute HBV DNA level at the start of TDF rescue treatment (P<0.001; OR, 0.715; 95% CI, 0.646-0.791) was only significantly associated with VR. Conclusions: TDF rescue therapy has comparable efficacy in the SDR and MDR CHB patients, and the presence of MDR did not alter the response rates. HBV DNA level at the start of TDF rescue therapy was the only predictor of subsequent VR.
Sang-Kyun Han,Min-Jae Cho,Seung-An Baek,Ju-Ung Yun,Du-Song Cha 강원대학교 산림과학연구소 2019 Journal of Forest Science Vol.35 No.3
A tree-length harvesting system using the HAM300, which is mounted on a farm tractor prototype machine, have been recently introduced in South Korea for thinning old (>30 years) forests. However, no research has previously been conducted on the characteristics of residual stand damage associated with cable yarding systems on thinning treatment stands in South Korea. Therefore, there were assessed on the degree and quantity of residual stand damage caused by felling and yarding process to broaden the knowledge of residual stand damage on semi-mechanized skyline thinning operations. This study investigated scar size, direction, area, shape type and their distribution on the residual stand damage caused by felling and yarding operations. Damage to residual trees was generated for 7.4% and 6.9% of residual trees in felling and yarding operations, respectively. Damaged direction of scars was located in front-side (38.9%) and up-side (34.7%) for felling operations while the highest scar damage was found on down-side (44.6%) for yarding operations. Scar heights of felling damage were higher than those of yarding damage. In yarding operation, the most of the scars was located within l0m from the center of the skyline corridor. These results should be useful information for forest managers and landowners to reduce residual stand damages and retain valuable timber volume from thinning treatments.
Du Wenjing,Sang Yiquan,Bai Yun-Huan 대한독성 유전단백체 학회 2022 Molecular & cellular toxicology Vol.18 No.3
Background Sepsis is a commonly seen severe case in clinical practice and the main cause of health loss worldwide. Objective We investigated the biological function of LRG1 and its underlying molecular mechanisms in sepsis-renal injury. Mice of sepsis model group were subjected to cecal ligation and puncture (CLP) surgery after anesthetization. THP-1 cell was induced by LPS for vitro model. Results The mRNA and protein levels of LRG1 in renal tissue of sepsis model were reduced. LRG1 could reduce the inflammation reaction in model of sepsis-renal injury. In addition, LRG1 up-regulation reduced inflammation reaction and ROS production levels in vitro model via the activation of HIF-1α and suppression of NLRP3 inflammasome. Knockout of LRG1 increased inflammation reaction and ROS production levels in vitro model via the inactivation of HIF-1α and induction of NLRP3 inflammasome. Furthermore, the inhibition of HIF-1α reduced the effects of LRG1 on NLRP3 inflammasome in vitro model. Conclusions The present study suggests that LRG1 expression reduced inflammation of sepsis-renal injury via activation of NLRP3 inflammasome by HIF-1α, thereby may be a promising therapeutic target of sepsis-renal injury.
Excellent Seam Weldable Nano-Composite Coated Zn-Ni Plating Steels for Automotive Fuel Tank
( Du-hwan Jo ),( Sang-man Yun ),( Kee-cheol Park ),( Myung-soo Kim ),( Jong-sang Kim ) 한국부식방식학회(구 한국부식학회) 2019 Corrosion Science and Technology Vol.18 No.1
Steels for automotive fuel tank require unique properties such as corrosion resistance for fuel, welding for joining, forming for press, and painting for exterior. Recently, automakers have been requiring excellent seam weldable steels to enhance manufacturing productivity of fuel tank. Thus, POSCO developed a new type of functional steels coated with nano-composite thin layer on Zn-Ni plating steels. The nano-composite coating solution was prepared by mechanical fine dispersion of solutions consisting of polymeric resin and nano-composite materials in aqueous media. The composite solution was coated on the plating steel surface by using roll coater and cured through induction furnace. These new developed plating steels were evaluated for quality performances such as seam and spot weldability, press formability, and corrosion resistance. These new functional steels coated with nano-composite layer exhibited excellent seam weldability and press formability. Detailed discussion of coating solution and experimental results suggest that nano-sized composite dispersion as coating layer plays a key role in enhancing the quality performance.